Cargando…

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouwer, Philip J. M., Caniels, Tom G., van der Straten, Karlijn, Snitselaar, Jonne L., Aldon, Yoann, Bangaru, Sandhya, Torres, Jonathan L., Okba, Nisreen M. A., Claireaux, Mathieu, Kerster, Gius, Bentlage, Arthur E. H., van Haaren, Marlies M., Guerra, Denise, Burger, Judith A., Schermer, Edith E., Verheul, Kirsten D., van der Velde, Niels, van der Kooi, Alex, van Schooten, Jelle, van Breemen, Mariëlle J., Bijl, Tom P. L., Sliepen, Kwinten, Aartse, Aafke, Derking, Ronald, Bontjer, Ilja, Kootstra, Neeltje A., Wiersinga, W. Joost, Vidarsson, Gestur, Haagmans, Bart L., Ward, Andrew B., de Bree, Godelieve J., Sanders, Rogier W., van Gils, Marit J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299281/
https://www.ncbi.nlm.nih.gov/pubmed/32540902
http://dx.doi.org/10.1126/science.abc5902
_version_ 1783547355420688384
author Brouwer, Philip J. M.
Caniels, Tom G.
van der Straten, Karlijn
Snitselaar, Jonne L.
Aldon, Yoann
Bangaru, Sandhya
Torres, Jonathan L.
Okba, Nisreen M. A.
Claireaux, Mathieu
Kerster, Gius
Bentlage, Arthur E. H.
van Haaren, Marlies M.
Guerra, Denise
Burger, Judith A.
Schermer, Edith E.
Verheul, Kirsten D.
van der Velde, Niels
van der Kooi, Alex
van Schooten, Jelle
van Breemen, Mariëlle J.
Bijl, Tom P. L.
Sliepen, Kwinten
Aartse, Aafke
Derking, Ronald
Bontjer, Ilja
Kootstra, Neeltje A.
Wiersinga, W. Joost
Vidarsson, Gestur
Haagmans, Bart L.
Ward, Andrew B.
de Bree, Godelieve J.
Sanders, Rogier W.
van Gils, Marit J.
author_facet Brouwer, Philip J. M.
Caniels, Tom G.
van der Straten, Karlijn
Snitselaar, Jonne L.
Aldon, Yoann
Bangaru, Sandhya
Torres, Jonathan L.
Okba, Nisreen M. A.
Claireaux, Mathieu
Kerster, Gius
Bentlage, Arthur E. H.
van Haaren, Marlies M.
Guerra, Denise
Burger, Judith A.
Schermer, Edith E.
Verheul, Kirsten D.
van der Velde, Niels
van der Kooi, Alex
van Schooten, Jelle
van Breemen, Mariëlle J.
Bijl, Tom P. L.
Sliepen, Kwinten
Aartse, Aafke
Derking, Ronald
Bontjer, Ilja
Kootstra, Neeltje A.
Wiersinga, W. Joost
Vidarsson, Gestur
Haagmans, Bart L.
Ward, Andrew B.
de Bree, Godelieve J.
Sanders, Rogier W.
van Gils, Marit J.
author_sort Brouwer, Philip J. M.
collection PubMed
description The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.
format Online
Article
Text
id pubmed-7299281
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-72992812020-06-29 Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability Brouwer, Philip J. M. Caniels, Tom G. van der Straten, Karlijn Snitselaar, Jonne L. Aldon, Yoann Bangaru, Sandhya Torres, Jonathan L. Okba, Nisreen M. A. Claireaux, Mathieu Kerster, Gius Bentlage, Arthur E. H. van Haaren, Marlies M. Guerra, Denise Burger, Judith A. Schermer, Edith E. Verheul, Kirsten D. van der Velde, Niels van der Kooi, Alex van Schooten, Jelle van Breemen, Mariëlle J. Bijl, Tom P. L. Sliepen, Kwinten Aartse, Aafke Derking, Ronald Bontjer, Ilja Kootstra, Neeltje A. Wiersinga, W. Joost Vidarsson, Gestur Haagmans, Bart L. Ward, Andrew B. de Bree, Godelieve J. Sanders, Rogier W. van Gils, Marit J. Science Research Articles The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention. American Association for the Advancement of Science 2020-08-07 2020-06-15 /pmc/articles/PMC7299281/ /pubmed/32540902 http://dx.doi.org/10.1126/science.abc5902 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Brouwer, Philip J. M.
Caniels, Tom G.
van der Straten, Karlijn
Snitselaar, Jonne L.
Aldon, Yoann
Bangaru, Sandhya
Torres, Jonathan L.
Okba, Nisreen M. A.
Claireaux, Mathieu
Kerster, Gius
Bentlage, Arthur E. H.
van Haaren, Marlies M.
Guerra, Denise
Burger, Judith A.
Schermer, Edith E.
Verheul, Kirsten D.
van der Velde, Niels
van der Kooi, Alex
van Schooten, Jelle
van Breemen, Mariëlle J.
Bijl, Tom P. L.
Sliepen, Kwinten
Aartse, Aafke
Derking, Ronald
Bontjer, Ilja
Kootstra, Neeltje A.
Wiersinga, W. Joost
Vidarsson, Gestur
Haagmans, Bart L.
Ward, Andrew B.
de Bree, Godelieve J.
Sanders, Rogier W.
van Gils, Marit J.
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
title Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
title_full Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
title_fullStr Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
title_full_unstemmed Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
title_short Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
title_sort potent neutralizing antibodies from covid-19 patients define multiple targets of vulnerability
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299281/
https://www.ncbi.nlm.nih.gov/pubmed/32540902
http://dx.doi.org/10.1126/science.abc5902
work_keys_str_mv AT brouwerphilipjm potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT canielstomg potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT vanderstratenkarlijn potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT snitselaarjonnel potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT aldonyoann potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT bangarusandhya potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT torresjonathanl potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT okbanisreenma potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT claireauxmathieu potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT kerstergius potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT bentlagearthureh potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT vanhaarenmarliesm potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT guerradenise potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT burgerjuditha potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT schermeredithe potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT verheulkirstend potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT vanderveldeniels potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT vanderkooialex potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT vanschootenjelle potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT vanbreemenmariellej potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT bijltompl potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT sliepenkwinten potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT aartseaafke potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT derkingronald potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT bontjerilja potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT kootstraneeltjea potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT wiersingawjoost potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT vidarssongestur potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT haagmansbartl potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT wardandrewb potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT debreegodelievej potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT sandersrogierw potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability
AT vangilsmaritj potentneutralizingantibodiesfromcovid19patientsdefinemultipletargetsofvulnerability